- Home
- TRIN vs RLAY Comparison
TRIN vs RLAY Comparison
Compare TRIN & RLAY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TRIN
- RLAY
- Stock Information
- Founded
- TRIN 2007
- RLAY 2015
- Country
- TRIN United States
- RLAY United States
- Employees
- TRIN N/A
- RLAY N/A
- Industry
- TRIN Finance/Investors Services
- RLAY Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- TRIN Finance
- RLAY Health Care
- Exchange
- TRIN Nasdaq
- RLAY Nasdaq
- Market Cap
- TRIN 1.0B
- RLAY 811.8M
- IPO Year
- TRIN 2021
- RLAY 2020
- Fundamental
- Price
- TRIN $15.83
- RLAY $3.92
- Analyst Decision
- TRIN Buy
- RLAY Strong Buy
- Analyst Count
- TRIN 3
- RLAY 10
- Target Price
- TRIN $15.17
- RLAY $20.11
- AVG Volume (30 Days)
- TRIN 518.6K
- RLAY 1.5M
- Earning Date
- TRIN 02-26-2025
- RLAY 02-28-2025
- Dividend Yield
- TRIN 12.89%
- RLAY N/A
- EPS Growth
- TRIN 12.74
- RLAY N/A
- EPS
- TRIN 1.72
- RLAY N/A
- Revenue
- TRIN $205,164,000.00
- RLAY $10,006,000.00
- Revenue This Year
- TRIN $35.45
- RLAY N/A
- Revenue Next Year
- TRIN $18.14
- RLAY N/A
- P/E Ratio
- TRIN $9.19
- RLAY N/A
- Revenue Growth
- TRIN 20.08
- RLAY N/A
- 52 Week Low
- TRIN $13.05
- RLAY $3.50
- 52 Week High
- TRIN $16.26
- RLAY $10.79
- Technical
- Relative Strength Index (RSI)
- TRIN 60.41
- RLAY 41.60
- Support Level
- TRIN $15.59
- RLAY $3.85
- Resistance Level
- TRIN $16.26
- RLAY $4.19
- Average True Range (ATR)
- TRIN 0.25
- RLAY 0.28
- MACD
- TRIN -0.00
- RLAY -0.02
- Stochastic Oscillator
- TRIN 65.87
- RLAY 24.80
About TRIN Trinity Capital Inc.
Trinity Capital Inc is a closed-end, non-diversified management investment company. The company is engaged in providing debt, including loans and equipment financings, to growth-stage companies, including venture-backed companies and companies with institutional equity investors. Its equipment financings involve loans for general or specific use, including acquiring equipment, secured by the equipment or other assets of the portfolio company.
About RLAY Relay Therapeutics Inc.
Relay Therapeutics Inc is a clinical-stage precision medicine company transforming the drug discovery process by combining leading-edge computational and experimental technologies with the goal of bringing life-changing therapies to patients. the Dynamo platform integrates an array of leading-edge computational and experimental approaches designed to drug-protein targets that have previously been intractable or inadequately addressed. The company is advancing a pipeline of medicine candidates to address targets in precision oncology and genetic disease, including product candidates, RLY-4008, RLY-2608, and GDC-1971 (formerly known as RLY-1971).